Human cytotoxic T-cell (CTL) clones that lyse autologous cells infected with herpes simplex virus (HSV) type I or 2 were generated by stimulating lymphocytes with a recombinant vaccinia virus (recombinant vaccinia-gD-1 virus) that expresses HSV type 1 glycoprotein D (gD-I). Furthermore, CTL clones generated with HSV type 1 or with cloned gD-1 lysed autologous cells infected with the recombinant vaccinia-gD-1 virus. Our findings thus showed that gD serves as a target antigen for human CTLs and that a recombinant vaccinia-gD virus activates HSV-specific human CTL.
Herpes simplex virus (HSV) types 1 and 2 (HSV-1 and HSV-2, respectively) cause latent ganglionic infections in humans that can persist for life and result in recurrent oral and genital infections despite the usual presence of virusneutralizing antibodies (6, 16) . Studies with experimental animals have indicated that T-cell-mediated immunity, in addition to humoral immunity, plays an important role in resistance to HSV infections; adoptive transfer of HSVimmune T cells, including cytotoxic T cells (CTL), can clear infectious virus and contribute to the recovery of HSVinfected mice (9-11, 15, 17, 18, 21) . At present, there is little information concerning which HSV antigens elicit T-cellmediated immunity in humans and serve as target antigens for human CTL. HSV encodes approximately six major glycoproteins which are expressed on the surfaces of the virus and virus-infected cells (23) . One of these, glycoprotein D of HSV-1 (gD-1). has been cloned and expressed by transfected or recombinant vaccinia virus-infected mammalian cells (7, 12, 13, 19) . Immunization of experimental animals with purified gD-1 or with live recombinant vaccinia virus that expresses gD-1 (recombinant vaccinia-gD-1 virus) was found to protect against HSV-1 infections (2. 5. 7. 8. 13, 19) . We report here that many human CTL clones generated with HSV-1 and all the CTL clones generated with purified gD-1 lysed autologous cells infected with the recombinant vaccinia-gD-1 virus, thus demonstrating that gD serves as a target antigen for HSV-specific human CTL. Furthermore, HSV-specific CTL clones were generated by stimulating human lymphocytes with a recombinant vaccinia-gD virus.
The recombinant vaccinia virus used for this study, vgD52, was constructed by using the WR strain of vaccinia virus and contains the entire coding sequence of the gD-1 gene of HSV-1 (strain KOS) (7) . It induces the synthesis of an immunologically reactive glycosylated polypeptide that comigrates with authentic gD-1, and it induces serum neutralizing antibodies in mice. Furthermore, this recombinant was found to protect mice against a potentially lethal challenge with live HSV-1 or HSV-2. and a single vaccination X Corresponding author. also prevented the development of latent infections in the majority of the vaccinated animals (7).
To determine whether gD serves as a target antigen for HSV-specific human CTL, we tested the ability of HSV-1-directed CTL clones to lyse target cells infected with the recombinant vaccinia-gD-1 virus. We previously showed that human CTL clones isolated from HSV-1-stimulated peripheral blood lymphocytes (PBL) lysed either HSV-1-or both HSV-1-and HSV-2-infected autologous target cells and target cells sharing certain human leukocyte antigen (HLA) class II antigens with the clones (26, 27) . The CTL clones used for this study were generated as previously described (26) (27) (28) . Briefly, 105 PBL from HSV-1-seropositive individuals were stimulated in microwells twice at weekly intervals either with purified gD-1 (1 .g/ml) that was cloned and expressed in mammalian cells (13) or with UV-lightinactivated HSV-1 (105 PFU/ml prior to UV light inactivation) in RPMI 1640 medium containing 10% heat-inactivated normal human serum (complete medium). Three days later, the stimulated cells were cloned by seeding single cells in microwells containing 5 x 104 X-irradiated (2,500 R) autologous PBL as antigen-presenting cells and UV lightinactivated HSV-1 in complete medium containing 5% lectin-free T-cell growth factor (TCGF; Cellular Products, Buffalo. N.Y.). The clones were expanded in TCGF and fed every 10 days with X-irradiated autologous PBL and UV light-inactivated HSV-1.
The results in Table 1 show examples of CTL clones that were generated by stimulation of PBL with purified, cloned gD-1 and that lysed 51Cr-labeled autologous target cells infected with HSV-1 or with the recombinant vaccinia-gD-1 virus but not with parental vaccinia virus. A total of 33 CTL clones were isolated from donor 2 PBL stimulated with gD-1i and all 33 lysed the recombinant vaccinia-gD-1 virusinfected cells. In contrast. HSV-1-specific CTL clones that were generated by stimulation with HSV-1 glycoprotein B-1 (30) failed to lyse target cells infected with the recombinant vaccinia-gD-1 virus (data not shown). Experiments were carried out to determine whether HSVspecific human CTL can be generated by stimulation with the recombinant vaccinia-gD virus. PBL from HSVseropositive individuals were stimulated with purified, UV light-inactivated recombinant vaccinia-gD-1 virus (105 PFU/ml prior to UV light inactivation) that fails to produce plaques but induces the expression of gD, as determined by immunofluorescence with a monoclonal antibody to gD-1. In our initial experiments, PBL stimulated twice with UV light-inactivated recombinant virus were cloned and maintained with UV light-inactivated recombinant vaccinia-gD-1 virus, X-irradiated autologous PBL as antigen-presenting cells, and TCGF. However, of 11 CTL clones isolated in this way, 6 lysed vaccinia virus-infected cells, presumably owing to the presence of vaccinia virus-specific memory T cells in individuals previously vaccinated against smallpox with vaccinia virus. Therefore, to select for the growth of HSVspecific CTL clones following two stimulations of PBL with Table 2 shows several examples of such CTL clones that lysed HSVand recombinant virus-infected cells but not parental vaccinia virus-infected cells. Of 27 CTL clones generated from donor 2, 25 lysed HSV-1-and recombinant virus-infected cells but not parental vaccinia virus-infected cells; of these 25, 10 also lysed autologous HSV-2-infected cells. The isolation of CTL clones that apparently recognized typecommon epitopes of gD on HSV-1 and HSV-2 is consistent with the high degree of homology between the genes for gD-1 and HSV-2 glycoprotein D (gD-2) (12) and the broad serological cross-reactivity of gD-1 and gD-2 (20) . None of these clones lysed allogeneic HSV-1-or recombinant virusinfected cells that share no HLA class I or II antigens with the clones. Consistent with our earlier finding that HSV-1-stimulated clones are react with monoclonal antibodies to T-cell antigens T3 and T4 (26, 27) , the clones generated with the recombinant virus were also approximately 98% T3', T4+ and 0% T8+. Subclones isolated from the clones exhibited the same phenotype and pattern of specificity as did the parental clones.
In addition to our finding that gD serves as a major target antigen for HSV-specific CTL clones, this study also shows that a recombinant vaccinia-gD can activate HSV-specific CTL from humans who have been naturally exposed to HSV. The determination of whether such a recombinant virus will prime HSV-specific human CTL in vivo would require human vaccine trials. Recent findings that a recombinant vaccinia virus expressing an influenza virus protein can successfully vaccinate against influenza virus infections (22) and can prime CTL against influenza virus in experimental animals (1) support the contention that a recombinant vaccinia-gD virus will prime HSV-specific CTL in humans.
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